The Nobel Laureate's Biotech Baby Just Flatlined

Those are real numbers. Caribou said the results were on par with approved CAR-T therapies that use a patient's own cells. For an off-the-shelf approach, that's genuinely impressive.

But impressive science and a funded company are two very different things.

When the Money Dries Up, the Music Stops

The core issue wasn't bad data. It was bad timing and brutal economics.

Moving vispa-cel into a larger, later-stage trial would have cost hundreds of millions of dollars. Caribou tried to raise that money. It couldn't. The company pointed to a "challenging financing environment" for allogeneic CAR-T therapies, which is a polite way of saying investors stopped writing checks for this corner of biotech.

And honestly, can you blame them? Manufacturing cell therapies is wildly expensive. The regulatory path is long and uncertain. Even companies with approved CRISPR products have struggled to turn a profit. When the market loses faith in an entire category, individual companies get crushed regardless of their data.

Caribu's board approved a restructuring that discontinues both vispa-cel and its earlier-stage multiple myeloma program, CB-011. Most employees will be gone by the end of 2026's fourth quarter. The company's market cap, once buoyed by billions in hype, has collapsed.

Caribou Isn't Alone (and That's the Scary Part)

If this were just one company's bad luck, it would be a footnote. Instead, it's a chapter in a much longer story.

The CRISPR sector has been living through what some have called a "prolonged winter." Spotlight Therapeutics shut down after disappointing preclinical results. Prime Medicine laid off 25% of its workforce and benched its lead program. Even the giants aren't immune: Intellia Therapeutics and CRISPR Therapeutics, two of the biggest names in gene editing, have both cut staff and reshuffled their pipelines.

The pattern is consistent. The science works (sometimes brilliantly), but the business model can't keep up. High manufacturing costs, enormous trial expenses, and cautious investors have created a gap between what gene editing can do and what companies can afford to prove.

The Doudna Portfolio: A Split Decision

Jennifer Doudna didn't just co-found Caribou. She helped launch multiple CRISPR companies, each with a different bet on how the technology would reach the real world.

Intellia Therapeutics, focused on editing genes directly inside the body (called "in vivo" editing), appears to be the most resilient of the group so far. Mammoth Biosciences, which applies CRISPR to diagnostics as well as therapeutics, has an entirely different risk profile.

Editas Medicine, another Doudna-linked company (though she departed early), has had its own struggles but remains operational.

The takeaway? Doudna's companies have split into two camps: therapeutics companies burning cash in pursuit of FDA approval, and diagnostics companies that can reach revenue without the same financial cliff. Caribou, unfortunately, was deep in the first camp with no parachute.

What This Really Means

Caribu's shutdown doesn't mean CRISPR is dead. Not even close. The technology is real, it works, and Vertex's approved sickle cell therapy (Casgevy) proved it can change lives.

But there's a brutal lesson here about the distance between a Nobel Prize and a profitable company. Caribou had world-class science, credible clinical data, and a founding team that literally invented the field. None of that mattered when the capital markets said "no."

For the broader cell and gene therapy sector, Caribou's fate is a warning. You can have the best drug candidate on the planet, but if you can't fund the next trial, the science dies on the vine. Investors aren't just asking "does it work?" anymore. They're asking "can you afford to prove it?"

That second question is killing companies faster than any failed trial ever could.

Why Telix Just Paid $2.35 Billion for a Factory

Telix Pharmaceuticals is spending up to $2.35 billion to acquire ITM Isotope Technologies, and the real story isn't the pipeline. It's a high-stakes bet on controlling the fragile supply chain that the entire radiopharmaceutical industry depends on.